ArticleEuropean journal of pediatrics2026
Semaphorin 4D (CD100) expression as a predictor for the response to induction therapy in pediatric patients with B-acute lymphoblastic leukemia.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Semaphorin 4D (Sema4D)/(CD100) expression is upregulated in different human cancers, and it is associated with poor prognosis; however, its prognostic value in B-acute lymphoblastic leukemia (B-ALL) remains unclear. We aimed to study the prognostic value of Sema4D expression to predict response to induction therapy in pediatric patients with B-ALL. Sixty newly diagnosed pediatric patients with B-ALL were enrolled, and their peripheral mononuclear cells (PBMCs) were isolated for assessment of Sema4D expression by multiparametric flow cytometry before initiating therapy. Then, we followed up with the patients for their response to induction therapy. Sema4D expression is significantly higher in non-responders to induction therapy than in responders. Using the receiver operating characteristic (ROC) curve, Sema4D expression > 18% significantly identifies patients at risk for induction failure. Logistic regression analyses confirmed that Sema4D expression is significantly associated with poor response to induction therapy.
conclusionPBMCs' Sema4D expression can be considered a potential marker for predicting the response to induction therapy in pediatric patients with B-ALL. So, it may serve to optimize treatment decisions for those patients. WHAT IS KNOWN: • Semaphorin 4D (Sema4D)/(CD100) expression is upregulated in different human cancers, and it is associated with poor prognosis. • However, its prognostic value in B-acute lymphoblastic leukemia (B-ALL) in pediatrics remains unclear. WHAT IS NEW: • We aimed to study the prognostic value of Sema4D expression to predict response to induction therapy in pediatric patients with B-ALL. • Sema4D expression can be considered a potential marker for predicting the response to induction therapy in pediatric patients with B-ALL. So, it may serve to optimize treatment decisions for those patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.